AgeX Therapeutics Publishes Theoretical Basis of Human Cell Age-Reversal in the Journal Regenerative Medicine


  • Somatic restriction theory of aging unifies numerous aspects of aging, regeneration and cancer biology
  • Highlights significance of AgeX’s induced Tissue Regeneration (iTRTM) technology for development of advanced therapies for aging and cancer
  • AgeX has formed Reverse Bioengineering, Inc. to develop and commercialize iTR technology

ALAMEDA, Calif.--(BUSINESS WIRE)--Sep. 4, 2019-- AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company focused on therapeutics for human aging and regeneration, announced today that founder and CEO Michael D. West, Ph.D., and colleagues have authored a paper in the peer-reviewed scientific journal Regenerative Medicine on the theoretical foundation of the Company’s induced Tissue Regeneration (iTRTM) technology. The paper presents the work of the company’s scientists in describing a unified theory of aging and regeneration that could pave the way for the development of new therapies for a variety of age-related degenerative diseases and conditions.

“The longevity sector is advancing at an accelerating pace, but for the most part, without a consensus on the fundamental root causes of aging,” commented Dr. West. “We believe that it is now possible to collate the diverse observations about aging into a unified model. In the paper titled, ‘Toward a Unified Theory of Aging and Regeneration’ we outline such a theory that underlies the technological underpinnings of the company’s induced tissue regeneration (iTR) program.”

The paper explores the mechanisms of aging and shares important insights into molecular biology of cell aging and immortalization, as well as the mechanisms of cell age reversal by somatic cell nuclear transfer and transcriptional reprogramming. Lastly, the paper explores the prospects of cell age reversal in vivo, that is in the patient, as opposed to in vitro (the laboratory dish).

“We are fortunate to have at AgeX some of the first scientists in the world to envision applying reprogramming technology to the problems of aging,” commented Greg Bailey, M.D., Chairman of the Board of Directors. “Our ultimate aim is to not only lead in the basic research in this new field, but to also lead in the translation of the science into safe and effective therapeutics for the aging population. To accomplish the latter goal, we have incorporated a new subsidiary of AgeX, Reverse Bioengineering, Inc. with the primary mission of advancing this emerging technology.”

Co-authors on the paper are Hal Sternberg, PhD, Ivan Labat, PhD, Jeffrey Janus, Karen B. Chapman, PhD, Nafees N. Malik, MD, Aubrey D.N.J. de Grey, PhD, and Dana Larocca, PhD.

A video summarizing the technology described in the paper is available for viewing online. The paper was published online ahead of print on Wednesday, August 28, 2019. It may be found here.

About AgeX Therapeutics

AgeX Therapeutics, Inc. (NYSE American: AGE) is focused on developing and commercializing innovative therapeutics for human aging. Its PureStem® and UniverCytemanufacturing and immunotolerance technologies are designed to work together to generate highly defined, universal, allogeneic, off-the-shelf pluripotent stem cell-derived young cells of any type for application in a whole host of diseases with a high unmet medical need. AgeX has two preclinical cell therapy programs: AGEX-VASC1 (vascular progenitor cells) for tissue ischemia and AGEX-BAT1 (brown fat cells) for Type II diabetes. AgeX’s revolutionary longevity platform named induced Tissue Regeneration (iTR™) aims to unlock cellular immortality and regenerative capacity to reverse age-related changes within tissues. AGEX-iTR1547 is an iTR-based formulation in preclinical development. HyStem® is AgeX’s delivery technology to stably engraft PureStem cell therapies and slowly release iTR molecules in the body. AgeX is developing its core product pipeline for use in the clinic to extend human healthspan, and is seeking opportunities to form licensing and partnership agreements around its broad IP estate and proprietary technology platforms for non-core clinical applications.

For more information, please visit or connect with the company on Twitter, LinkedIn, Facebook, and YouTube.

Forward-Looking Statements

Certain statements contained in this release are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not historical fact including, but not limited to statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates” should also be considered forward-looking statements. Forward-looking statements involve risks and uncertainties. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the business of AgeX Therapeutics, Inc. and its subsidiaries, particularly those mentioned in the cautionary statements found in more detail in AgeX’s reports filed with the Securities and Exchange Commissions (copies of which may be obtained at Subsequent events and developments may cause these forward-looking statements to change. AgeX specifically disclaims any obligation or intention to update or revise these forward-looking statements as a result of changed events or circumstances that occur after the date of this release, except as required by applicable law.

Source: AgeX Therapeutics

Media Contact for AgeX:

Bill Douglass
Gotham Communications, LLC
(646) 504-0890